プレフィルドシリンジ市場における技術革新 - 今後のR&Dトレンドを形成する生物製剤と自己注射器
Innovation in the Prefilled Syringe Market - Biologics and Autoinjection Devices Shaping Future R&D Trends
|出版日||ページ情報||英文 28 Pages
|プレフィルドシリンジ市場における技術革新 - 今後のR&Dトレンドを形成する生物製剤と自己注射器 Innovation in the Prefilled Syringe Market - Biologics and Autoinjection Devices Shaping Future R&D Trends|
|出版日: 2012年12月14日||ページ情報: 英文 28 Pages||
GBI Research, the leading business intelligence provider, has released its latest research, "Innovation in the Prefilled Syringe Market - Biologics and Autoinjection Devices Shaping Future R&D Trends", which provides insights into possible future avenues of R&D in the prefilled syringe market. This includes an overview of problems and possible solutions, as well as discussion of how the devices have developed to date to address problems with contamination, safety, fragility and ease of use.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.
The market for prefilled syringes is being driven by the rise in popularity of autoinjection devices for the home-use market. As health authorities seek to reduce costs, facilitating patients in self-administering their medication is one major way of reducing the strain on resources for providers. Additionally, patients prefer this option as it does not require them to travel to hospital and can be accommodated in their own home.
Innovation is also being driven by safety. This area has seen increasing innovation in response to regulations and guidelines concerning needlestick injury. This is an area of rising concern as the number of logged needlestick injuries in healthcare workers is high and thought to be considerably under-reported. Measures to ensure healthcare provider safety have been put in place, and pharmaceutical companies are responding by improving the safety of their prefilled syringes in order to increase their appeal and gain market share. Safety devices have moved from active devices, which require activation by the user, to passive, which are automatically activated. The next steps are being made in integrating the safety device into the needle during manufacture.
The development of injectable biologic therapies is a major factor in the future prospects of prefilled syringes. Although oral biologics are something that companies are aiming for and there are some in development, many peptides are broken down too quickly in the stomach and are therefore not useful in treatment. The mainstay of biologic treatment is likely to remain injectable, whether intravenous, subcutaneous or intramuscular, for the foreseeable future. As such, companies need to overcome the limitations of prefilled syringes in order to provide convenient method of administration and win market share.
The rise of biologic therapies will power growth in the prefilled syringes market - but only if manufacturers can solve current product problems, says a new report from healthcare industry experts GBI Research.
As explained in the business intelligence firm's latest release*, the development of injectable biologic therapies is a major factor for the future prospects of prefilled syringes, as many peptides contained in oral formulations are broken down too quickly in the stomach, compromising their effectiveness.
Currently, many biologic therapies are incompatible with the silicone used in glass syringes, necessitating a move to plastic variations and the development of new polymers and coatings that minimize reactions between the syringe material and the drug that cause contamination.
Glass has been the primary material in syringe manufacturing for decades, but is slowly being replaced as the advantages of polymer-based alternatives become apparent. Other than the possibility of product contamination, glass syringes are more fragile and are prone to flaking, but existing plastic versions are not without their own faults.
Cyclo-olefin polymers and co-polymers are the most commonly used plastic syringe variants in the market today, with several companies offering prefilled syringes in this form. However, while they are more durable and less likely to feature manufacturing defects than their glass counterparts, they are also more expensive to produce and are economically unsuitable for low price drugs.
Polypropylene syringes have been around since the 1990s, and although cheaper than the aforementioned plastics, it is a less transparent material and more difficult to sterilize.
GBI Research's new report also predicts that the prefilled syringe market will be driven by the growth of home use and auto-injection devices that use a button-push mechanism - an innovative response to the common fear of needles.
This report includes an overview of problems and possible solutions, as well as discussion of how the devices have developed to date to address problems with contamination, safety, fragility and ease of use.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.